A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses
PLOS Pathogens · 11.02.2025 · 21 (2) · e1012571
DOI: 10.1371/journal.ppat.1012571 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 11.02.2025. Verfasst von Benjamin Van Loy und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Virus Replication, Antiviral Agents, Endoribonucleases, Viral Nonstructural Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Innovative Health Initiative, Fundació La Marató de TV3, FWO Research Foundation Flanders.
Abstract (Originalsprache)
The approval of COVID-19 vaccines and antiviral drugs has been crucial to end the global health crisis caused by SARS-CoV-2. However, to prepare for future outbreaks from drug-resistant variants and novel zoonotic coronaviruses (CoVs), additional therapeutics with a distinct antiviral mechanism are needed. Here, we report a novel guanidine-substituted diphenylurea compound that suppresses CoV replication by interfering with the uridine-specific endoribonuclease (EndoU) activity of the viral non-structural protein-15 (nsp15). This compound, designated EPB-113, exhibits strong and selective cell culture activity against human coronavirus 229E (HCoV-229E) and also suppresses the replication of SARS-CoV-2. Viruses, selected under EPB-113 pressure, carried resistance sites at or near the catalytic His250 residue of the nsp15-EndoU domain. Although the best-known function of EndoU is to avoid induction of type I interferon (IFN-I) by lowering the levels of viral dsRNA, EPB-113 was found to mainly act via an IFN-independent mechanism, situated during viral RNA synthesis. Using a combination of biophysical and enzymatic assays with the recombinant nsp15 proteins from HCoV-229E and SARS-CoV-2, we discovered that EPB-113 enhances the EndoU cleavage activity of hexameric nsp15, while reducing its thermal stability. This mechanism explains why the virus escapes EPB-113 by acquiring catalytic site mutations which impair compound binding to nsp15 and abolish the EndoU activity. Since the EPB-113-resistant mutant viruses induce high levels of IFN-I and its effectors, they proved unable to replicate in human macrophages and were readily outcompeted by the wild-type virus upon co-infection of human fibroblast cells. Our findings suggest that antiviral targeting of nsp15 can be achieved with a molecule that induces a conformational change in this protein, resulting in higher EndoU activity and impairment of viral RNA synthesis. Based on the appealing mechanism and resistance profile of EPB-113, we conclude that nsp15 is a challenging but highly relevant drug target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
- Institute of Biomedicine of the University of Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain.
- Biochemistry, Molecular and Structural Biology, Department of Chemistry, KU Leuven, Leuven, Belgium.
- Sustainable Chemistry for Metals and Molecules, Department of Chemistry, KU Leuven, Leuven, Belgium.
- Department of Pharmaceutical and Pharmacological Sciences, Rega Institute, KU Leuven, Leuven, Belgium.
ORCID-Profile: Lieve Naesens
Förderung
- European Union’s Innovative Health Initiative
- Fundació La Marató de TV3
- FWO Research Foundation Flanders
- Onderzoeksraad, KU Leuven
- Innovative Health Initiative
Zitieren
APA
Van Loy, B., Pujol, E., Kamata, K., Lee, X. Y., Bakirtzoglou, N., Van Berwaer, R., Vandeput, J., Mestdagh, C., Persoons, L., De Wijngaert, B., Goovaerts, Q., Noppen, S., Jacquemyn, M., Ahmadzadeh, K., Bernaerts, E., Martín-López, J., Escriche, C., Vanmechelen, B., Krasniqi, B., …, & Stevaert, A. (2025). A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses. PLOS Pathogens, 21(2), e1012571. https://doi.org/10.1371/journal.ppat.1012571
Vancouver
Van Loy B, Pujol E, Kamata K, Lee XY, Bakirtzoglou N, Van Berwaer R, et al. A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses. PLOS Pathogens. 2025;21(2):e1012571. doi:10.1371/journal.ppat.1012571
BibTeX
@article{VanLoy2025,
author = {Van Loy, Benjamin and Pujol, Eugènia and Kamata, Kenichi and Lee, Xiao Yin and Bakirtzoglou, Nikolai and Van Berwaer, Ria and Vandeput, Julie and Mestdagh, Cato and Persoons, Leentje and De Wijngaert, Brent and Goovaerts, Quinten and Noppen, Sam and Jacquemyn, Maarten and Ahmadzadeh, Kourosh and Bernaerts, Eline and Martín-López, Juan and Escriche, Celia and Vanmechelen, Bert and Krasniqi, Besir and Singh, Abhimanyu K and Daelemans, Dirk and Maes, Piet and Matthys, Patrick and Dehaen, Wim and Rozenski, Jef and Das, Kalyan and Voet, Arnout and Vázquez, Santiago and Naesens, Lieve and Stevaert, Annelies},
title = {A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {2},
pages = {e1012571},
doi = {10.1371/journal.ppat.1012571}
}
EUVIMED